China Medical System Holdings Limited (AIM: CMSH) is pleased to announce that， for the purpose of improving the understanding of diagnosis and treatment of Inflammatory Bowel Disease(IBD) among Chinese doctors， and increasing international academic exchanges while promoting Salofalk in China market， the 24th-28th Falk Symposium was hold in Shanghai， Guangzhou， Nanjing， Zhengzhou and Beijing， from March 28 to April 10， co-sponsored by Falk Foundation e.V. Germany and CMS.
The symposium invited Mr.G.Adler， the professor of internal medicine of University Ulm and the core member of the Scientific Committee of German Ministry of Health， to gave a speech on Diagnosis and Treatment of IBD:Effect of Mesalazine. 490 doctors in the field of digestive diseases attended the symposium series. The academic viewpoints of Professor G.Adler obtained unanimous approvals from local authoritative experts. They shared opinions and communicated about the differences in treatment of IBD between East and West.
This series of Falk Symposium inspires new approaches for diagnosis and treatment of IBD in China， and Mesalazine(Salofalk) is believed to have great potential in future market as the remedium basis for treatment of IBD.